Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age
BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to <12 years of age) with obesity. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide or placebo for a period of 104 weeks, after which participants stopped taking semaglutide or placebo for a 7-week washout period. Both groups received counseling for lifestyle modification. The primary end point was the percent change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. RESULTS: Among 167 children who underwent randomization, 112 were assigned to receive semaglutide and 55 to receive placebo. At week 68, the mean percent change in BMI was -13.5% with semaglutide and 2.7% with placebo (estimated between-group difference, -16.2 percentage points; 95% confidence interval [CI], -19.4 to -12.9; P<0.001). The percent change in BMI at week 104 was -9.4% with semaglutide and 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3). At week 68, a reduction in BMI category had occurred in 79% of the participants in the semaglutide group and in 23% of those in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001), with the BMI below the threshold for obesity (the 95th percentile for age and sex) in 38% of the participants who received semaglutide and in 2% of those who received placebo. Adverse events occurred in 96% of the participants receiving semaglutide and in 93% of those receiving placebo. Gastrointestinal adverse events were the most common, occurred more frequently with semaglutide than with placebo, and led to discontinuation in 1 participant in the semaglutide group. CONCLUSIONS: Among children (6 to <12 years of age) with obesity, treatment with semaglutide for 68 weeks resulted in a significantly greater mean percent reduction in BMI than placebo. (Funded by Novo Nordisk; STEP Young ClinicalTrials.gov number, NCT05726227.).
Authors
- Ania M. Jastreboff (ORCID: https://orcid.org/0000-0003-1446-0991)
- Tina Buch
- Nina Majlund Harder-Lauridsen (ORCID: https://orcid.org/0000-0002-8651-5544)
- Antje Körner (ORCID: https://orcid.org/0000-0001-6001-0356)
- Christine Frithioff‐Bøjsøe (ORCID: https://orcid.org/0000-0002-5005-7780)
- Martin Wabitsch (ORCID: https://orcid.org/0000-0001-6795-8430)
- Jens-Christian Holm
- Shilpa Middolu
- Michelle Van Name
- Daniel Weghuber
- Aaron S. Kelly
Institutions
- University of Copenhagen (DK)
- University of Minnesota (US)
- Novo Nordisk (Denmark) (DK)
- Universität Ulm (DE)
- Paracelsus Medical University (AT)
- Yale Cancer Center (US)
- Helmholtz Zentrum München (DE)
- Yale University (US)
- University Hospital Leipzig (DE)
- Holbæk Sygehus (DK)
- University Hospital Ulm (DE)
- Novo Nordisk (India) (IN)
- Novo Nordisk Foundation Center for Basic Metabolic Research (DK)
- Leipzig University (DE)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1056/nejmoa2604058
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk